Sigmoid Venous Thrombosis in JAK2 V617F Mutated Polycythemia Vera
A 60-year-old female presented with headaches, blurry vision, diplopia, and dizziness for six weeks. Her workup revealed an elevated hematocrit, thrombocytosis, high ferritin, and normal erythropoietin. She was diagnosed with polycythemia vera with the JAK2 V617F mutation. The patient underwent magn...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Case Reports in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2022/4948115 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832567769446481920 |
|---|---|
| author | Cilomar Martins De Oliveira Filho Alexander Gavralidis |
| author_facet | Cilomar Martins De Oliveira Filho Alexander Gavralidis |
| author_sort | Cilomar Martins De Oliveira Filho |
| collection | DOAJ |
| description | A 60-year-old female presented with headaches, blurry vision, diplopia, and dizziness for six weeks. Her workup revealed an elevated hematocrit, thrombocytosis, high ferritin, and normal erythropoietin. She was diagnosed with polycythemia vera with the JAK2 V617F mutation. The patient underwent magnetic resonance venography, which showed left-sided sigmoid venous thrombosis. She was placed on low-molecular-weight heparin, with a plan to transition to oral anticoagulation after four weeks and repeat imaging in three months to assess for resolution. Thrombotic events may occur in patients with polycythemia vera, and a JAK2 mutation further heightens that risk. Even so, intracranial venous thrombosis is not among the most common events, and it should be kept in the differential for any patient with myeloproliferative neoplasms presenting with new neurological symptoms. |
| format | Article |
| id | doaj-art-fbeb2a6442984d9387560214fa7d54e6 |
| institution | Kabale University |
| issn | 2090-6579 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Hematology |
| spelling | doaj-art-fbeb2a6442984d9387560214fa7d54e62025-02-03T01:00:43ZengWileyCase Reports in Hematology2090-65792022-01-01202210.1155/2022/4948115Sigmoid Venous Thrombosis in JAK2 V617F Mutated Polycythemia VeraCilomar Martins De Oliveira Filho0Alexander Gavralidis1Mass General BrighamMass General BrighamA 60-year-old female presented with headaches, blurry vision, diplopia, and dizziness for six weeks. Her workup revealed an elevated hematocrit, thrombocytosis, high ferritin, and normal erythropoietin. She was diagnosed with polycythemia vera with the JAK2 V617F mutation. The patient underwent magnetic resonance venography, which showed left-sided sigmoid venous thrombosis. She was placed on low-molecular-weight heparin, with a plan to transition to oral anticoagulation after four weeks and repeat imaging in three months to assess for resolution. Thrombotic events may occur in patients with polycythemia vera, and a JAK2 mutation further heightens that risk. Even so, intracranial venous thrombosis is not among the most common events, and it should be kept in the differential for any patient with myeloproliferative neoplasms presenting with new neurological symptoms.http://dx.doi.org/10.1155/2022/4948115 |
| spellingShingle | Cilomar Martins De Oliveira Filho Alexander Gavralidis Sigmoid Venous Thrombosis in JAK2 V617F Mutated Polycythemia Vera Case Reports in Hematology |
| title | Sigmoid Venous Thrombosis in JAK2 V617F Mutated Polycythemia Vera |
| title_full | Sigmoid Venous Thrombosis in JAK2 V617F Mutated Polycythemia Vera |
| title_fullStr | Sigmoid Venous Thrombosis in JAK2 V617F Mutated Polycythemia Vera |
| title_full_unstemmed | Sigmoid Venous Thrombosis in JAK2 V617F Mutated Polycythemia Vera |
| title_short | Sigmoid Venous Thrombosis in JAK2 V617F Mutated Polycythemia Vera |
| title_sort | sigmoid venous thrombosis in jak2 v617f mutated polycythemia vera |
| url | http://dx.doi.org/10.1155/2022/4948115 |
| work_keys_str_mv | AT cilomarmartinsdeoliveirafilho sigmoidvenousthrombosisinjak2v617fmutatedpolycythemiavera AT alexandergavralidis sigmoidvenousthrombosisinjak2v617fmutatedpolycythemiavera |